Braun Stacey Associates Inc. Invests $12.96 Million in Gilead Sciences, Inc. $GILD

Posted by on Aug 29th, 2026

Braun Stacey Associates Inc. bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the second quarter, according to its most recent filing with the SEC. The firm bought 102,562 shares of the biopharmaceutical company’s stock, valued at approximately $12,958,000.

Several other hedge funds have also bought and sold shares of GILD. Vermillion & White Wealth Management Group LLC lifted its position in Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares in the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences during the 4th quarter worth approximately $25,000. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences in the second quarter worth approximately $25,000. Kimelman & Baird LLC purchased a new stake in shares of Gilead Sciences in the second quarter worth approximately $25,000. Finally, Quattro Advisors LLC bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $26,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

  • Positive Sentiment: The FDA approved Bixlenvo, a once-daily single-tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. It is the first and only single-tablet option for patients on complex regimens who cannot use currently available alternatives, potentially expanding Gilead’s HIV franchise and supporting its longer-term lenacapavir strategy. Reuters FDA approval article
  • Positive Sentiment: The European Commission approved Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients, strengthening Gilead’s oncology portfolio and adding a potential growth opportunity outside its core HIV business. EU Trodelvy approval article
  • Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target of approximately $158. However, GILD’s strong multi-year advance may have raised expectations and limited the immediate upside from the Bixlenvo approval. Gilead valuation article
  • Negative Sentiment: Director Anthony Welters sold 18,000 shares worth about $2.68 million, reducing his position by roughly 58%. The sale occurred under a pre-arranged Rule 10b5-1 plan, making it a limited bearish signal, but it may still weigh modestly on investor sentiment. SEC insider transaction filing

Insider Activity at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the transaction, the director directly owned 10,066 shares in the company, valued at $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the transaction, the chief executive officer directly owned 592,133 shares of the company’s stock, valued at $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,000 shares of company stock valued at $14,238,120 in the last 90 days. 0.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

GILD has been the topic of several analyst reports. HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Morgan Stanley dropped their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research note on Monday, July 27th. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a report on Wednesday, August 5th. Weiss Ratings lowered shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Twenty-four analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $158.04.

Read Our Latest Report on GILD

Gilead Sciences Stock Performance

Shares of GILD opened at $145.68 on Friday. The stock has a 50 day moving average of $134.25 and a 200 day moving average of $136.62. The company has a market capitalization of $180.64 billion, a price-to-earnings ratio of -54.56 and a beta of 0.32. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.01 earnings per share. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post -0.5 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is -122.85%.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Featured Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.